Site-specific Data Items (SSDIs)
Each Site-specific Data Item (SSDI) applies only to selected primary sites, histologies, and years of diagnosis. Depending on applicability and standard-setter requirements, SSDIs may be left blank.
SEER has developed a staging tool referred to as SEER*RSA that provides information (primary site/histology/other factors defined) about each cancer schema. The following tables list the
site-specific schema discriminators and site-specific data items (SSDIs) that are new and/or are required for collection in 2023. For more information about schemas and schema IDs, go to the SSDI Manual, Appendix A.
Table 1 and Table 2 list Schema Discriminators with the corresponding NAACCR item number and description implemented in 2018 and modified in 2021, respectively. Schema Discriminators are required for staging.
Tables 3, 4, and 5 list SSDIs implemented in 2022, 2023, and 2024, respectively. Table 6 lists additional SSDIs required for transmission. For additional required data items, see NAACCR Version 24 Required Status Table
and the SSDI Manual. Refer to SEER RSA and the SSDI manual for codes and coding instructions.
Table 1: Schema Discriminators Implemented in 2018
| Schema Discriminator | NAACCR Item # | Schema Discriminator Description |
|---|---|---|
Schema Discriminator 1 | 3926 | Occult Head and Neck Lymph Nodes |
Schema Discriminator 1 | 3926 | Nasopharynx/Pharyngeal Tonsil |
Schema Discriminator 2 | 3927 | Oropharyngeal p16 |
Schema Discriminator 1 | 3926 | EsophagusGEJunction (EGJ)/Stomach |
Schema Discriminator 2 | 3927 | Histology Discriminator for 8020/3 |
Schema Discriminator 1 | 3926 | BileDuctsDistal/BileDuctsPerihilar/CysticDuct |
Schema Discriminator 1 | 3926 | Primary Peritoneum Tumor |
Schema Discriminator 1 | 3926 | Urethra/Prostatic Urethra |
Schema Discriminator 1 | 3926 | Melanoma Ciliary Body/Melanoma Iris |
Schema Discriminator 1 | 3926 | Lacrimal Gland/Sac |
Schema Discriminator 1 | 3926 | Thyroid Gland/Thyroglossal Duct |
Schema Discriminator 1 | 3926 | Plasma Cell Myeloma Terminology |
Schema Discriminator 1 | 3926 | Histology Discriminator for 9591/3 |
Table 2: Schema Discriminators Modified for 2021
| Schema Discriminator | NAACCR Item # | New Schema Discriminator Description |
|---|---|---|
| Schema Discriminator 2* | 3927* | Soft Tissue Abdomen and Thoracic Soft Tissue Trunk and Extremities Soft Tissue Other |
*Schema Discriminator 2 [3927] was implemented in 2018. As of 2021, it is also required for C473, C475, C493-C495 applicable to Soft Tissue schemas.
Table 3: Site-specific Data Items Implemented in 2022
| Schema | NAACCR Item # | SSDI |
|---|---|---|
Cervix (9th) | 3956 | p16 |
Lymphoma-CLL/SLL | 3955 | Derived Rai Stage |
Cervix (8th); Cervix (9th), Vagina, Vulva | 3957 | LN Status: Pelvic |
Cervix (8th); Cervix (9th), Vagina | 3958 | LN Status: Para-Aortic |
Vagina, Vulva | 3959 | LN Status: Femoral-Inguinal |
Note: The data items are collected by SEER from CoC-accredited hospitals except Derived Rai Stage.
Table 4: Site-specific Data Items Implemented in 2023
Schema | NAACCR Item # | SSDI |
Appendix | 3960 | Histologic Subtype (Appendix 8480) |
Melanoma Skin | 3961 | Clinical Margin Width |
Anus V9 (existing SSDI added to schema) | 3956 | p16 |
Table 5: Site-specific Data Items Implemented in 2024
Schema | NAACCR Item # | SSDI |
Brain V9; CNS Other V9 (significant update) | 3816 | Brain Molecular Markers |
Vulva V9 (existing SSDI added to schema) | 3956 | p16 |
Brain V9 (new) | 3964 | Brain Primary Tumor Location |
Table 6: Additional Site-specific Data Items Required for Transmission (See NAACCR Vol II Required Status Table for more information)
NAACCR Item # | SSDI | NAACCR Item # | SSDI |
3800 | Schema ID* | 3873 | LN Assessment Method Pelvic |
3801 | Chromosome 1p: Loss of Heterozygosity (LOH) | 3874 | LN Distant Assessment Method |
3802 | Chromosome 19q: Loss of Heterozygosity (LOH) | 3875 | LN Distant: Mediastinal, Scalene |
3803 | Adenoid Cystic Basaloid Pattern | 3876 | LN Head and Neck Levels I-III |
3804 | Adenopathy | 3877 | LN Head and Neck Levels IV-V |
3805 | AFP Post-Orchiectomy Lab Value | 3878 | LN Head and Neck Levels VI-VII |
3806 | AFP Post-Orchiectomy Range | 3879 | LN Head and Neck Other |
3807 | AFP Pre-Orchiectomy Lab Value | 3880 | LN Isolated Tumor Cells (ITC) |
3808 | AFP Pre-Orchiectomy Range | 3881 | LN Laterality |
3809 | AFP Pretreatment Interpretation | 3882 | LN Positive Axillary Level I-II |
3810 | AFP Pretreatment Lab Value | 3883 | LN Size |
3811 | Anemia | 3885 | Lymphocytosis |
3812 | B symptoms | 3886 | Major Vein Involvement |
3813 | Bilirubin Pretreatment Total Lab Value | 3887 | Measured Basal Diameter |
3814 | Bilirubin Pretreatment Unit of Measure | 3888 | Measured Thickness |
3815 | Bone Invasion | 3889 | Methylation of O6-Methylguanine-Methyltransferase |
3940 | BRAF Mutational Analysis | 3890 | Microsatellite Instability (MSI) |
3816 | Brain Molecular Markers | 3891 | Microvascular Density |
3817 | Breslow Tumor Thickness | 3892 | Mitotic Count Uveal Melanoma |
3818 | CA-125 Pretreatment Interpretation | 3893 | Mitotic Rate Melanoma |
3819 | CEA Pretreatment Interpretation | 3894 | Multigene Signature Method |
3820 | CEA Pretreatment Lab Value | 3895 | Multigene Signature Results |
3821 | Chromosome 3 Status | 3896 | NCCN International Prognostic Index (IPI) |
3822 | Chromosome 8q Status | 3897 | Number of Cores Examined |
3823 | Circumferential Resection Margin (CRM) | 3898 | Number of Cores Positive |
3824 | Creatinine Pretreatment Lab Value | 3899 | Number of Examined Para-Aortic Nodes |
3825 | Creatinine Pretreatment Unit of Measure | 3900 | Number of Examined Pelvic Nodes |
3826 | Estrogen Receptor Percent Positive or Range | 3901 | Number of Positive Para-Aortic Nodes |
3827 | Estrogen Receptor Summary | 3902 | Number of Positive Pelvic Nodes |
3829 | Esophagus and EGJ Tumor Epicenter | 3903 | OncotyPe Dx Recurrence Score- DCIS |
3830 | Extranodal Extension Clin (non-Head and Neck) | 3904 | OncotyPe Dx Recurrence Score-Invasive |
3831 | Extranodal Extension Head and Neck Clinical | 3905 | OncotyPe Dx Risk Level-DCIS |
3832 | Extranodal Extension Head and Neck Pathological | 3906 | OncotyPe Dx Risk Level-Invasive |
3833 | Extranodal Extension Path (non-Head and Neck) | 3907 | Organomegaly |
3834 | Extravascular Matrix Patterns | 3908 | Percent Necrosis Post Neoadjuvant |
3835 | Fibrosis Score | 3909 | Perineural Invasion |
3836 | FIGO Stage | 3910 | Peripheral Blood Involvement |
3837 | Gestational Trophoblastic Prognostic Scoring Index | 3911 | Peritoneal Cytology |
3838 | Gleason Patterns Clinical | 3913 | Pleural Effusion |
3839 | Gleason Patterns Pathological | 3914 | Progesterone Receptor Percent Positive or Range |
3840 | Gleason Score Clinical | 3915 | Progesterone Receptor Summary |
3841 | Gleason Score Pathological | 3918 | Profound Immune Suppression |
3842 | Gleason Tertiary Pattern | 3919 | EOD Prostate Pathologic Extension |
3846 | hCG Post-Orchiectomy Lab Value | 3920 | PSA (Prostatic Specific Antigen) Lab Value |
3847 | hCG Post-Orchiectomy Range | 3921 | Residual Tumor Volume Post Cytoreduction |
3848 | hCG Pre-Orchiectomy Lab Value | 3922 | Response to Neoadjuvant Therapy |
3849 | hCG Pre-Orchiectomy Range | 3923 | S Category Clinical |
3855 | HER2 Overall Summary | 3924 | S Category Pathological |
3856 | Heritable Trait | 3925 | Sarcomatoid Features |
3857 | High Risk Cytogenetics | 3926 | Schema Discriminator 1 |
3858 | High Risk Histologic Features | 3927 | Schema Discriminator 2 |
3859 | HIV Status | 3928 | Schema Discriminator 3 |
3860 | International Normalized Ratio Prothrombin Time | 3929 | Separate Tumor Nodules |
3861 | Ipsilateral Adrenal Gland Involvement | 3930 | Serum Albumin Pretreatment Level |
3862 | JAK2 | 3931 | Serum Beta-2 Microglobulin Pretreatment Level |
3863 | Ki-67 | 3932 | LDH Lab Value |
3864 | Invasion Beyond Capsule | 3933 | Thrombocytopenia |
3865 | KIT Gene Immunohistochemistry | 3934 | Tumor Deposits |
3866 | KRAS | 3936 | Ulceration |
3867 | LDH Post-Orchiectomy Range | 3937 | Visceral and Parietal Pleural Invasion |
3868 | LDH Pre-Orchiectomy Range | 3938 | ALK Rearrangement |
3869 | LDH Level | 3939 | EGFR Mutational Analysis |
3870 | LDH Upper Limits of Normal | 3940 | BRAF Mutational Analysis |
3871 | LN Assessment Method Femoral-Inguinal | 3941 | NRAS Mutational Analysis |
3872 | LN Assessment Method Para-Aortic | 3942 | CA-19-9 PreTx Lab Value |
*Derived
Overview
Content Tools
Activity